Cytomegalovirus Infections
Information
- Disease name
- Cytomegalovirus Infections
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04904614 | Active, not recruiting | Phase 4 | Letermovir Use in Heart Transplant Recipients | October 1, 2021 | December 30, 2025 |
| NCT04364178 | Active, not recruiting | Phase 1/Phase 2 | Viral Specific T-Lymphocytes to Treat Adenovirus or CMV | August 12, 2020 | January 1, 2032 |
| NCT03915366 | Active, not recruiting | Phase 2/Phase 3 | Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia | March 1, 2020 | July 31, 2025 |
| NCT05099965 | Active, not recruiting | Phase 2 | Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) | November 2, 2021 | October 14, 2025 |
| NCT03475212 | Active, not recruiting | Phase 1/Phase 2 | Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation | June 20, 2018 | February 2024 |
| NCT05089630 | Active, not recruiting | Phase 1/Phase 2 | A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults | October 14, 2021 | June 19, 2029 |
| NCT06337955 | Active, not recruiting | Non Primary HCMV Infection: Natural History and Immune Response | June 6, 2017 | December 2024 | |
| NCT02943057 | Active, not recruiting | Phase 4 | Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis | October 2016 | September 2024 |
| NCT00001100 | Completed | Phase 3 | A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. | November 2005 | |
| NCT00001531 | Completed | Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction | June 1996 | September 2000 | |
| NCT00001890 | Completed | Phase 2 | Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections | May 1999 | March 2001 |
| NCT00002024 | Completed | N/A | Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections | ||
| NCT00002025 | Completed | N/A | Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient | ||
| NCT00002095 | Completed | N/A | A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus | ||
| NCT00002096 | Completed | Phase 1 | A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine | ||
| NCT00002146 | Completed | Phase 4 | Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study | ||
| NCT00002251 | Completed | N/A | A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir | ||
| NCT00002268 | Completed | Phase 1 | A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria | ||
| NCT00002352 | Completed | N/A | A Study of Lobucavir in Patients With AIDS | ||
| NCT00002373 | Completed | Phase 1 | The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients | ||
| NCT00004278 | Completed | Phase 3 | Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection | December 1991 | |
| NCT00004642 | Completed | Phase 1/Phase 2 | Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease | February 1995 | |
| NCT00005274 | Completed | Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) | May 1989 | March 2003 | |
| NCT00005309 | Completed | Prospective Study of HIV Infection in Hemophiliacs | July 1990 | March 1995 | |
| NCT00005496 | Completed | Inflammation, Infection, and Future Cardiovascular Risk | September 1998 | August 2002 | |
| NCT00005547 | Completed | Infection and Cardiovascular Disease | April 1999 | June 2003 | |
| NCT00005572 | Completed | A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection | |||
| NCT00006145 | Completed | Phase 3 | Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV | August 2000 | February 2006 |
| NCT00006314 | Completed | Cytomegalovirus Spread and Reactivation in Blood Cells | July 1999 | June 2004 | |
| NCT00029406 | Completed | Transfusion Infections Pediatric Prospective Study (TRIPPS) | April 2001 | April 2013 | |
| NCT00031421 | Completed | Neonatal CMV-Ganciclovir Follow-up Study | September 2001 | November 2005 | |
| NCT00031434 | Completed | Phase 1/Phase 2 | Valganciclovir in Congenital CMV Infants | July 2002 | July 2007 |
| NCT00034437 | Completed | Immune Response to Cytomegalovirus | April 2002 | April 2003 | |
| NCT00078533 | Completed | Phase 1 | Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant | April 2004 | June 2011 |
| NCT00000584 | Completed | Phase 3 | Transfusion-Transmitted Cytomegalovirus Prevention in Neonates | July 1983 | June 1988 |
| NCT00125502 | Completed | Phase 2 | Recombinant CMV gB Vaccine in Postpartum Women | August 1999 | January 2010 |
| NCT00133497 | Completed | Phase 2 | gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females | June 2006 | June 2013 |
| NCT00170170 | Completed | Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation | November 2004 | June 2007 | |
| NCT00194142 | Completed | Cytomegalovirus (CMV) Infection in Amniotic Fluid | July 2007 | May 2008 | |
| NCT00227370 | Completed | Phase 3 | Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation | July 2003 | December 2008 |
| NCT00264290 | Completed | Phase 4 | Valganciclovir to Reduce T Cell Activation in HIV Infection | August 2006 | November 2008 |
| NCT00284687 | Completed | Phase 3 | Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients | July 2006 | March 2010 |
| NCT00294515 | Completed | Phase 3 | IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients | March 31, 2006 | August 31, 2009 |
| NCT00090766 | Completed | Phase 2/Phase 3 | A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients | May 2004 | May 2005 |
| NCT00000593 | Completed | N/A | Viral Activation Transfusion Study (VATS) | November 1994 | March 2001 |
| NCT00000805 | Completed | Phase 1 | A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease | March 1998 | |
| NCT00000981 | Completed | Phase 2 | The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS | February 1993 | |
| NCT00000995 | Completed | N/A | A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection | February 1990 | |
| NCT00001038 | Completed | Phase 3 | A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients | ||
| NCT00001082 | Completed | Phase 3 | The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients | December 1996 | August 1999 |
| NCT00001089 | Completed | A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients | |||
| NCT00353977 | Completed | Phase 2 | Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors | May 2004 | March 2008 |
| NCT00372229 | Completed | Phase 3 | A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation | May 2006 | October 2015 |
| NCT00377741 | Completed | Phase 1 | A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. | December 2004 | June 2006 |
| NCT00411645 | Completed | Phase 3 | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients | December 13, 2006 | May 23, 2009 |
| NCT00431353 | Completed | Phase 4 | VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients | April 2004 | August 2008 |
| NCT00439803 | Completed | Phase 1 | A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV) | April 2007 | July 2008 |
| NCT00497796 | Completed | Phase 3 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients | July 23, 2007 | September 14, 2009 |
| NCT00566072 | Completed | N/A | The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial | May 2001 | May 2003 |
| NCT00673868 | Completed | Phase 1 | Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants | October 2007 | August 6, 2008 |
| NCT00674648 | Completed | Phase 1 | Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants | August 2007 | March 2014 |
| NCT00815165 | Completed | Cytomegalovirus Cell-Mediated Immunity | June 2006 | August 2011 | |
| NCT01034709 | Completed | Evaluation of the Artus® CMV PCR Test | December 2009 | June 2014 | |
| NCT01070797 | Completed | Phase 1 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) | January 2011 | April 2014 |
| NCT01251744 | Completed | N/A | Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus | December 9, 2010 | June 17, 2015 |
| NCT01325636 | Completed | Phase 1/Phase 2 | Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus | September 2010 | May 2014 |
| NCT01535885 | Completed | Phase 1 | Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV | February 2012 | October 2019 |
| NCT01594437 | Completed | Phase 1 | Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody | May 2012 | March 2013 |
| NCT01602614 | Completed | Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection | April 2013 | March 2019 | |
| NCT01663740 | Completed | Phase 4 | A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls | January 30, 2012 | December 30, 2016 |
| NCT01753167 | Completed | Phase 2 | A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients | December 14, 2012 | October 15, 2014 |
| NCT01819519 | Completed | N/A | Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus | March 2013 | March 2015 |
| NCT01972035 | Completed | Phase 2 | ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation | August 1, 2014 | February 28, 2021 |
| NCT01986010 | Completed | Phase 1 | Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) | November 25, 2013 | March 14, 2017 |
| NCT02062294 | Completed | An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients | July 31, 2010 | September 30, 2011 | |
| NCT02076971 | Completed | Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive | January 2014 | March 2016 | |
| NCT02084446 | Completed | Phase 4 | Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant | December 2012 | July 2017 |
| NCT02134184 | Completed | Phase 4 | The Influence of Chronic CMV Infection on Influenza Vaccine Responses | October 2012 | December 2012 |
| NCT02439372 | Completed | Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis | April 2015 | June 2016 | |
| NCT02538172 | Completed | N/A | Cell-mediated Immunity for Prevention of CMV Disease | October 2015 | January 2021 |
| NCT02600065 | Completed | Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy | November 2014 | December 31, 2022 | |
| NCT02642822 | Completed | The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University | October 2014 | April 2016 | |
| NCT02683096 | Completed | Screening for Congenital Cytomegalovirus Infection in Newborns | February 2016 | February 2018 | |
| NCT02683291 | Completed | Phase 4 | Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients | January 2014 | January 2016 |
| NCT02684734 | Completed | Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis | December 2015 | December 2019 | |
| NCT02715752 | Completed | A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin | January 2016 | March 2016 | |
| NCT02826798 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults | June 23, 2016 | August 24, 2017 |
| NCT03004261 | Completed | Phase 4 | CMV-CTL for the Treatment of CMV Infection After HSCT | November 2016 | December 31, 2021 |
| NCT03631316 | Completed | N/A | Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir | March 1, 2018 | November 1, 2018 |
| NCT03699254 | Completed | Phase 3 | Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. | April 5, 2019 | May 29, 2023 |
| NCT03728426 | Completed | Phase 2 | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | January 11, 2019 | March 28, 2022 |
| NCT03840174 | Completed | Phase 1 | Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) | March 8, 2019 | November 7, 2019 |
| NCT03916497 | Completed | Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients | April 30, 2019 | July 30, 2019 | |
| NCT04067869 | Completed | Phase 3 | Cytomegalovirus Infection in Patients With HIV-1 Infection | February 16, 2010 | December 13, 2010 |
| NCT04478474 | Completed | Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients | September 15, 2020 | September 15, 2022 | |
| NCT04658810 | Completed | Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy, | May 2, 2021 | August 2, 2021 | |
| NCT04693637 | Completed | Phase 2/Phase 3 | Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | January 15, 2021 | January 19, 2023 |
| NCT04906304 | Completed | N/A | Comparison of Safety and Efficacy of de Novo Everolimus | January 1, 2020 | August 1, 2020 |
| NCT06027879 | Enrolling by invitation | Phase 1/Phase 2 | Anti-viral T-cell Therapy by Gamma Capture | January 8, 2024 | June 1, 2029 |
| NCT03806764 | Enrolling by invitation | N/A | Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | April 17, 2018 | December 31, 2023 |
| NCT06058858 | Not yet recruiting | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis | October 1, 2023 | January 1, 2025 | |
| NCT06407232 | Not yet recruiting | Phase 3 | Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | June 2024 | June 2026 |
| NCT06341543 | Not yet recruiting | N/A | Quantiferon CMV to Identify Treatment Need For Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT) | April 25, 2024 | June 15, 2026 |
| NCT04439916 | Recruiting | Breakthrough CMV Lung Transplant -Multicentre | January 25, 2021 | December 2024 | |
| NCT03266640 | Recruiting | Phase 2 | Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) | November 1, 2018 | December 31, 2024 |
| NCT05532540 | Recruiting | Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study | January 1, 2023 | January 1, 2033 | |
| NCT05626530 | Recruiting | Phase 4 | Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients | February 2, 2023 | December 15, 2025 |
| NCT05701228 | Recruiting | Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ Transplantation | June 26, 2023 | June 2026 | |
| NCT03798301 | Recruiting | Phase 1 | Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells | February 6, 2020 | September 2026 |
| NCT04690933 | Recruiting | AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients | September 24, 2020 | December 31, 2024 | |
| NCT06339892 | Recruiting | N/A | HCMV Breakthrough Infections During Letermovir Prophylaxis | January 9, 2023 | March 2026 |
| NCT05183490 | Recruiting | Phase 1 | R-MVST Cells for Treatment of Viral Infections | May 3, 2022 | December 2026 |
| NCT06066957 | Recruiting | Phase 2 | Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | April 4, 2024 | August 15, 2026 |
| NCT02982902 | Recruiting | Early Phase 1 | T Cell Therapy of Opportunistic Cytomegalovirus Infection | May 27, 2020 | September 2025 |
| NCT02007356 | Recruiting | Phase 2 | A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® | December 2014 | December 2026 |
| NCT05370976 | Recruiting | Phase 2 | Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. | September 13, 2022 | September 2024 |
| NCT04030676 | Recruiting | N/A | QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis | July 17, 2019 | April 2026 |
| NCT06145178 | Recruiting | Phase 1 | A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants | November 22, 2023 | April 2025 |
| NCT01274377 | Terminated | Phase 1 | Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT | February 2011 | October 5, 2015 |
| NCT00302029 | Terminated | CMV Infection in Adolescent Males | June 2006 | December 2008 | |
| NCT03262194 | Terminated | Relevance of Gastric Aspirate in HCMV Detection | September 19, 2017 | June 7, 2019 | |
| NCT00264368 | Terminated | Phase 4 | Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy | December 2005 | June 2007 |
| NCT00241345 | Terminated | Phase 3 | Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant | June 2004 | December 2007 |
| NCT03950414 | Terminated | Phase 1 | A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients | September 27, 2019 | July 11, 2022 |
| NCT00237653 | Terminated | Phase 3 | MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus | February 2004 | December 2007 |
| NCT00201448 | Terminated | Phase 2/Phase 3 | Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women | June 2007 | October 2009 |
| NCT05305040 | Terminated | Phase 2/Phase 3 | Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | March 24, 2022 | January 30, 2024 |
| NCT02840825 | Terminated | Biochip for HCMV Detection in Breast Milk | March 8, 2016 | September 29, 2021 | |
| NCT04225780 | Unknown status | Phase 1/Phase 2 | Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection | February 1, 2020 | March 30, 2021 |
| NCT00299260 | Unknown status | Phase 2 | CMV Glycoprotein B Vaccine in Allograft Recipients | August 2006 | September 2011 |
| NCT01927588 | Unknown status | Phase 4 | Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients | August 2013 | November 2015 |
| NCT03858907 | Unknown status | Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV | August 5, 2018 | November 30, 2020 | |
| NCT03698435 | Unknown status | (Val)Ganciclovir TDM in Transplant Recipients | May 25, 2018 | December 31, 2019 | |
| NCT02129465 | Unknown status | Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy | June 2014 | May 2019 | |
| NCT00228202 | Unknown status | Genotyping of Cytomegalovirus From Patients in Israel | September 2005 | ||
| NCT01353053 | Unknown status | Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection | July 2010 | ||
| NCT03576014 | Unknown status | Phase 1 | Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient | April 27, 2018 | July 24, 2019 |
| NCT01081379 | Unknown status | The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection | February 2014 | August 2022 | |
| NCT03146208 | Unknown status | Role of Endothelial Biomarkers in Patients With Coronary Artery Disease | July 1, 2017 | January 20, 2019 | |
| NCT05091177 | Unknown status | Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis | January 1, 2021 | December 31, 2021 | |
| NCT02671318 | Unknown status | Phase 4 | Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence | September 2015 | August 2020 |
| NCT00004573 | Unknown status | N/A | Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR | ||
| NCT03188679 | Unknown status | N/A | Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection | July 2017 | December 2019 |
| NCT05234723 | Unknown status | Ganciclovir Resistant Cytomegalovirus Infection in SOT Recipients. | February 1, 2022 | June 30, 2022 | |
| NCT04183738 | Withdrawn | Phase 4 | Inflammation and Co-Infections in D²EFT | February 1, 2021 | December 19, 2022 |
| NCT02346617 | Withdrawn | Phase 1/Phase 2 | Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection | January 1, 2022 | December 1, 2024 |
| NCT04936971 | Withdrawn | Phase 4 | Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response | September 2021 | September 2021 |
| NCT00000881 | Withdrawn | Phase 1 | A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D003586